Evidence map›Paper›PMID 32458051›Full record

ReviewBioprocess and biosystems engineering2021

Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights.

Wenshuo Chen, Haijin Chen, Shudan Fu, Xiaohua Lin, Zheng Zheng, Jinlong Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Bioprocess and biosystems engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules.Nanomaterials (Basel, Switzerland) · 2021
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wenshuo ChenDepartment of Gastrointestinal Surgery, Zhujiang Hospital, Southern Medical University, GuangZhou, 510280, China.
Haijin ChenDepartment of Gastrointestinal Surgery, Zhujiang Hospital, Southern Medical University, GuangZhou, 510280, China. chenhaijin@sina.com.
Shudan FuOphthalmology Department, Zhujiang Hospital, Southern Medical University, GuangZhou, 510280, China.
Xiaohua LinDepartment of Gastrointestinal Surgery, Zhujiang Hospital, Southern Medical University, GuangZhou, 510280, China.
Zheng ZhengDepartment of Gastrointestinal Surgery, Zhujiang Hospital, Southern Medical University, GuangZhou, 510280, China.
Jinlong ZhangDepartment of Gastrointestinal Surgery, Zhujiang Hospital, Southern Medical University, GuangZhou, 510280, China.
Southern Medical University · CNZhujiang Hospital · CN

Funding

Natural Science Foundation of Guangdong Province 2017A030313488
6 · The paper itself

Abstract

The therapeutic effect of inflammatory bowel disease has improved in the past decades, but most of patients cannot tolerate, do not respond to drugs, or relapse after treating with conventional therapy. Therefore, new and more effective treatment methods are still needed in treatment of IBD. In this review, we will discuss the relevant mechanisms and the latest research progress of biologics (anti-TNF treatments, interleukin inhibitors, integrin inhibitors, antisense oligonucleotide, and JAK inhibitors) for IBD, focus on the efficacy and safety of drugs for moderate-to-severe IBD, and summarize the clinical status and future development direction of biologics in IBD.

Indexed as

Gastrointestinal MicrobiomeInflammatory Bowel DiseasesBiological ProductsHumansInterleukin InhibitorsBiological ProductsInterleukin InhibitorsBiological agentCrohn’s diseasesInflammatory bowel diseaseUlcerative colitis

Identifiers

PMID32458051
OpenAlexW3030092781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.